Compare · ABT vs AMRX
ABT vs AMRX
Side-by-side comparison of Abbott Laboratories (ABT) and Amneal Pharmaceuticals Inc. (AMRX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and AMRX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT is the larger of the two at $153.59B, about 235.8x AMRX ($651.3M).
- Over the past year, ABT is down 35.0% and AMRX is up 109.2% - AMRX leads by 144.2 points.
- ABT has been more active in the news (7 items in the past 4 weeks vs 3 for AMRX).
- ABT has more recent analyst coverage (25 ratings vs 5 for AMRX).
- Company
- Abbott Laboratories
- Amneal Pharmaceuticals Inc.
- Price
- $88.09-1.73%
- $16.21-0.73%
- Market cap
- $153.59B
- $651.3M
- 1M return
- +5.08%
- +30.83%
- 1Y return
- -35.03%
- +109.16%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NYSE
- IPO
- News (4w)
- 7
- 3
- Recent ratings
- 25
- 5
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Amneal Pharmaceuticals Inc.
Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates in three segments: Generics, Specialty, and AvKARE. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories. The Specialty segment is involved in the development, promotion, distribution, and sale of branded pharmaceutical products primarily for central nervous system disorders, endocrinology, parasitic infections, and other therapeutic areas. It also offers licensed, owned, niche, and mature branded products, as well as Rytary for the treatment of Parkinson's disease; Zomig for the treatment of migraine headaches; Emverm a chewable tablets for the treatment of pinworm, whipworm, common roundworm, common hookworm, and American hookworm in single or mixed infections; and Unithroid for the treatment of hypothyroidism. The AvKARE segment provides pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. It is also involved in the wholesale distribution of bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names, as well as medical and surgical products; and packaging and wholesale distribution of pharmaceuticals and vitamins to its retail and institutional customers. The company sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. It operates in the United States, India, Ireland, and internationally. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is based in Bridgewater, New Jersey.
Latest ABT
- Abbott declares 410th consecutive quarterly dividend
- New research shows even stronger health outcomes for participants in a 'Food is Medicine' program when paired with support from community health workers
- New Abbott data show many people with diabetes may not recognize symptoms of diabetic ketoacidosis
- SEC Form SD filed by Abbott Laboratories
- Abbott secures CE Mark for world's first dual glucose-ketone sensing technology for people with diabetes
- ACS guideline reaffirms Abbott leadership in noninvasive colorectal cancer screening
- Abbott showcases expanding evidence across its cancer diagnostics portfolio at ASCO 2026
- SEC Form 4 filed by EXECUTIVE VICE PRESIDENT Moreland Mary K
- SEC Form SCHEDULE 13G filed by Abbott Laboratories
- SEC Form 10-Q filed by Abbott Laboratories
Latest AMRX
- Amneal Announces Full Study Population Interim Phase 4 ELEVATE-PD Results, Reinforcing Previously Reported Benefits of CREXONT® in Parkinson's Disease
- Amneal Announces U.S. FDA Approval of Romidepsin Injection Solution
- Amneal to Participate in Goldman Sachs 47th Annual Global Healthcare Conference 2026
- Director Autor Deborah M. sold $450,558 worth of shares (34,819 units at $12.94), decreasing direct ownership by 27% to 93,660 units (SEC Form 4)
- Director Buchi J Kevin converted options into 34,819 shares, increasing direct ownership by 86% to 75,077 units (SEC Form 4)
- Director Autor Deborah M. converted options into 34,819 shares, increasing direct ownership by 37% to 128,479 units (SEC Form 4)
- Director George Jeffrey P. converted options into 34,819 shares, increasing direct ownership by 11% to 344,614 units (SEC Form 4)
- Director Patel Gautam converted options into 34,819 shares, increasing direct ownership by 2% to 1,643,963 units (SEC Form 4)
- Director Kiely John converted options into 34,819 shares, increasing direct ownership by 15% to 260,252 units (SEC Form 4)
- Director Nark Ted C converted options into 34,819 shares, increasing direct ownership by 12% to 325,848 units (SEC Form 4)